BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis
Europe - BIT:1BMY - US1101221083 - Common Stock
39.66 EUR
+0.54 (+1.38%)
Taking everything into account, 1BMY scores 6 out of 10 in our fundamental rating. 1BMY was compared to 49 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of 1BMY get a neutral evaluation. Nothing too spectacular is happening here. 1BMY may be a bit undervalued, certainly considering the very reasonable score on growth Finally 1BMY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year 1BMY was profitable.
In the past year 1BMY had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 1BMY reported negative net income in multiple years.
Each year in the past 5 years 1BMY had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.33%, 1BMY is in line with its industry, outperforming 51.92% of the companies in the same industry.
With an excellent Return On Equity value of 28.96%, 1BMY belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
1BMY has a better Return On Invested Capital (16.07%) than 80.77% of its industry peers.
1BMY had an Average Return On Invested Capital over the past 3 years of 11.67%. This is below the industry average of 15.25%.
The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(16.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 16.07% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1.3 Margins
Looking at the Profit Margin, with a value of 10.58%, 1BMY is in line with its industry, outperforming 48.08% of the companies in the same industry.
1BMY's Operating Margin of 30.27% is amongst the best of the industry. 1BMY outperforms 82.69% of its industry peers.
In the last couple of years the Operating Margin of 1BMY has declined.
1BMY's Gross Margin of 73.92% is fine compared to the rest of the industry. 1BMY outperforms 67.31% of its industry peers.
In the last couple of years the Gross Margin of 1BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
1BMY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
1BMY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1BMY has less shares outstanding
Compared to 1 year ago, 1BMY has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.05 indicates that 1BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
1BMY has a worse Altman-Z score (2.05) than 61.54% of its industry peers.
1BMY has a debt to FCF ratio of 3.37. This is a good value and a sign of high solvency as 1BMY would need 3.37 years to pay back of all of its debts.
1BMY has a better Debt to FCF ratio (3.37) than 61.54% of its industry peers.
A Debt/Equity ratio of 2.56 is on the high side and indicates that 1BMY has dependencies on debt financing.
1BMY has a Debt to Equity ratio of 2.56. This is in the lower half of the industry: 1BMY underperforms 78.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.05 |
ROIC/WACC1.78
WACC9.04%
2.3 Liquidity
1BMY has a Current Ratio of 1.21. This is a normal value and indicates that 1BMY is financially healthy and should not expect problems in meeting its short term obligations.
1BMY has a worse Current ratio (1.21) than 61.54% of its industry peers.
A Quick Ratio of 1.11 indicates that 1BMY should not have too much problems paying its short term obligations.
1BMY's Quick ratio of 1.11 is fine compared to the rest of the industry. 1BMY outperforms 67.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 391.24% over the past year.
1BMY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
Looking at the last year, 1BMY shows a small growth in Revenue. The Revenue has grown by 2.57% in the last year.
1BMY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.06% yearly.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
Based on estimates for the next years, 1BMY will show a very strong growth in Earnings Per Share. The EPS will grow by 36.14% on average per year.
1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.00% yearly.
EPS Next Y477.2%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
EPS Next 5Y36.14%
Revenue Next Year-1.27%
Revenue Next 2Y-4.75%
Revenue Next 3Y-3.56%
Revenue Next 5Y-5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.84, the valuation of 1BMY can be described as very cheap.
Based on the Price/Earnings ratio, 1BMY is valued cheaper than 92.31% of the companies in the same industry.
When comparing the Price/Earnings ratio of 1BMY to the average of the S&P500 Index (27.20), we can say 1BMY is valued rather cheaply.
The Price/Forward Earnings ratio is 7.57, which indicates a rather cheap valuation of 1BMY.
Based on the Price/Forward Earnings ratio, 1BMY is valued cheaper than 92.31% of the companies in the same industry.
1BMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.71, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.84 | ||
| Fwd PE | 7.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1BMY is valued cheaper than 90.38% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1BMY indicates a rather cheap valuation: 1BMY is cheaper than 94.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.43 | ||
| EV/EBITDA | 6.12 |
4.3 Compensation for Growth
1BMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as 1BMY's earnings are expected to grow with 73.40% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y130.91%
EPS Next 3Y73.4%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.12%, 1BMY is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.04, 1BMY pays a better dividend. On top of this 1BMY pays more dividend than 88.46% of the companies listed in the same industry.
1BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.12% |
5.2 History
On average, the dividend of 1BMY grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1BMY pays out 98.12% of its income as dividend. This is not a sustainable payout ratio.
The dividend of 1BMY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
BIT:1BMY (8/11/2025, 7:00:00 PM)
39.66
+0.54 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners84.14%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap80.73B
Analysts67.5
Price Target46.21 (16.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.12% |
Yearly Dividend2.08
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-5.85%
PT rev (3m)-6.85%
EPS NQ rev (1m)-2.05%
EPS NQ rev (3m)-3.35%
EPS NY rev (1m)-5.33%
EPS NY rev (3m)-5.33%
Revenue NQ rev (1m)0.92%
Revenue NQ rev (3m)1.36%
Revenue NY rev (1m)2.17%
Revenue NY rev (3m)2.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.84 | ||
| Fwd PE | 7.57 | ||
| P/S | 1.96 | ||
| P/FCF | 6.43 | ||
| P/OCF | 5.89 | ||
| P/B | 5.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.12 |
EPS(TTM)5.8
EY14.62%
EPS(NY)5.24
Fwd EY13.2%
FCF(TTM)6.17
FCFY15.56%
OCF(TTM)6.73
OCFY16.97%
SpS20.19
BVpS7.38
TBVpS-10.89
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 16.07% | ||
| ROICexc | 20.14% | ||
| ROICexgc | 101.89% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-16.88%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.05 |
F-Score7
WACC9.04%
ROIC/WACC1.78
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y477.2%
EPS Next 2Y130.91%
EPS Next 3Y73.4%
EPS Next 5Y36.14%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.27%
Revenue Next 2Y-4.75%
Revenue Next 3Y-3.56%
Revenue Next 5Y-5%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year268.01%
EBIT Next 3Y49.33%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%